17,261 trials
Cryptococcal Meningitis
Primary: Number of Grade 3-5 Adverse Experiences That Are Definitely or Probably Related to Study Drug — 2; 1; 0; 0 Events
Choroidal Neovascularization · Macular Degeneration
Primary: Mean Number of Retreatments (Day 0 Excluded) — 3.97; 3.00; 4.05; 5.39 number of retreatments
Non-Hodgkin's Lymphoma
Primary: Overall Response Rate — 17 pariticipants
Pneumonia, Ventilator-Associated · Pneumonia, Bacterial · Pneumonia
Primary: Patients With Incidence of Treatment-emergent Adverse Events (TEAEs). — 42; 13; 37; 15 participants
Kennedy's Disease · Spinal and Bulbar Muscular Atrophy
Primary: Muscle Strength Change From Baseline — -2.2; 3.1; -4.5; 1.3 percent change — p=0.28
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants
Progressive Supranuclear Palsy · Corticobasal Degeneration
Primary: Ability to Tolerate Lithium Carbonate — 1 Subject
Heart Failure
Primary: Change in Left Ventricular End-diastolic Pressure (LVEDP) Using Pressure-volume Catheter. — 5.67 mmHg
Myelodysplastic Syndromes
Primary: Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence — 59 participants
Pulmonary Cancer
Primary: Percentage of Participants Who Had an Objective Response Rate(ORR) Based on Response Evaluation Criteria In Solid Tumors (RECIST) Criteria. — 0 Percent of Participants
Multiple Myeloma
Primary: Percent of Particpants Achieving Overall Combined Complete Response (CR) Following Induction — 51; 44 percentage of participants
Myelodysplastic Syndromes
Primary: Number of Participants In Best Hematological Response Categories as Determined by the Investigator Using International Working Group 2000 (IWG 2000) Criteria For…
Carcinoma, Renal Cell
Primary: Best Response - mITT (Modified Intent-to-treat) Population — 8 Participants
Allergic Asthma
Primary: Change in Logarithmically Transformed (log2) Allergen PC15 Concentration (Allergen Concentration Required to Evoke a 15% Decrease in FEV1) — 1.15; 1.85; 0.36…
Cardiovascular Diseases · Heart Diseases
Primary: Number of Participants With Non-coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding Events — 3; 4; 4; 3…